Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Dogs of the Dow Enhanced Income Strategy with Covered Calls

The Dogs of the Dow has long been a simple, rules-based approach to equity investing, built around owning the highest-yielding stocks in the Dow Jones Industrial Average. Each year, investors rotate into the 10 Dow components with the highest dividend yields, based on the assumption that these stocks are temporarily out of favor and may rebound over time.

While the strategy has traditionally focused on dividends and capital appreciation, it can be enhanced by layering in options income. By systematically selling covered calls against these high-yielding, large-cap stocks, investors can potentially increase cash flow, reduce volatility, and create a more consistent...

Fundamentals

See More
  • Market Capitalization, $K 259,917,440
  • Shares Outstanding, K 2,482,023
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 22,392 M
  • EBITDA $ 26,891 M
  • 60-Month Beta 0.29
  • Price/Sales 3.91
  • Price/Cash Flow 10.68
  • Price/Book 4.86

Options Overview Details

View History
  • Implied Volatility 24.96% (+1.11%)
  • Historical Volatility 30.96%
  • IV Percentile 12%
  • IV Rank 11.56%
  • IV High 53.48% on 04/10/25
  • IV Low 21.24% on 12/24/24
  • Expected Move (DTE 3) 1.62 (1.54%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 40,973
  • Volume Avg (30-Day) 79,385
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 625,677
  • Open Int (30-Day) 736,077
  • Expected Range 103.11 to 106.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.08
  • Number of Estimates 6
  • High Estimate 2.16
  • Low Estimate 1.98
  • Prior Year 1.72
  • Growth Rate Est. (year over year) +20.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.06 +9.09%
on 12/09/25
105.84 -0.99%
on 11/25/25
+7.03 (+7.19%)
since 11/21/25
3-Month
77.58 +35.07%
on 09/25/25
105.84 -0.99%
on 11/25/25
+24.83 (+31.05%)
since 09/23/25
52-Week
73.31 +42.94%
on 05/15/25
105.84 -0.99%
on 11/25/25
+5.42 (+5.45%)
since 12/23/24

Most Recent Stories

More News
Dogs of the Dow Enhanced Income Strategy with Covered Calls

The Dogs of the Dow has long been a simple, rules-based approach to equity investing, built around owning the highest-yielding stocks in the Dow Jones Industrial Average. Each year, investors rotate into...

VZ : 40.04 (+0.15%)
CVX : 149.80 (unch)
KO : 70.27 (+0.09%)
MRK : 104.79 (+0.07%)
PG : 142.83 (+0.10%)
JNJ : 206.02 (-0.63%)
NKE : 57.31 (+0.16%)
HD : 346.81 (+0.12%)
AMGN : 331.39 (+1.22%)
UNH : 324.45 (-0.22%)
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Enlicitide has potential to be first approved oral PCSK9 inhibitor designed to help meet critical unmet needs for patients and will be offered at an affordable price to eligible Americans through a direct-to-patient...

MRK : 104.79 (+0.07%)
Stocks Settle Higher on Upbeat Tech Outlook and Cooling Inflation

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up by +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +1.51%. December...

AMAT : 257.55 (-0.56%)
GOOGL : 309.13 (-0.21%)
CNK : 22.65 (+0.89%)
AAPL : 271.22 (+0.09%)
SNDK : 236.99 (-1.68%)
MRK : 104.79 (+0.07%)
$IUXX : 25,461.70 (+0.46%)
ASML : 1,056.84 (-0.01%)
DJT : 14.10 (-2.13%)
ZNH26 : 112-045 (-0.18%)
MSFT : 485.10 (+0.04%)
TSLA : 487.55 (-0.24%)
Stocks Rally as Chip Makers Soar and US Price Pressures Ease

The S&P 500 Index ($SPX ) (SPY ) today is up by +1.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.82%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +1.91%. December E-mini S&P futures...

MSTR : 162.16 (-1.31%)
AMAT : 257.55 (-0.56%)
GOOGL : 309.13 (-0.21%)
CNK : 22.65 (+0.89%)
AAPL : 271.22 (+0.09%)
SNDK : 236.99 (-1.68%)
GLXY : 24.42 (-0.77%)
MRK : 104.79 (+0.07%)
$IUXX : 25,461.70 (+0.46%)
COIN : 244.50 (-1.37%)
ASML : 1,056.84 (-0.01%)
DJT : 14.10 (-2.13%)
Stocks Rebound on Strength in Chip Stocks and a Benign US CPI Report

The S&P 500 Index ($SPX ) (SPY ) today is up by +0.79%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up by +0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +1.43%. December E-mini S&P futures...

MSTR : 162.16 (-1.31%)
AMAT : 257.55 (-0.56%)
CNK : 22.65 (+0.89%)
SNDK : 236.99 (-1.68%)
GLXY : 24.42 (-0.77%)
MRK : 104.79 (+0.07%)
$IUXX : 25,461.70 (+0.46%)
COIN : 244.50 (-1.37%)
ASML : 1,056.84 (-0.01%)
DJT : 14.10 (-2.13%)
ZNH26 : 112-045 (-0.18%)
ESH26 : 6,917.25 (-0.19%)
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

First and only immunotherapy plus ADC regimen, used perioperatively, to extend survival for cisplatin-eligible patients with MIBC

MRK : 104.79 (+0.07%)
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIRâ„¢ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval...

MRK : 104.79 (+0.07%)
2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore

2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore

NVDA : 182.30 (-0.76%)
MRK : 104.79 (+0.07%)
ABBV : 228.20 (+0.13%)
Covered Call Screener Results For Dec 10th

Covered calls are a great strategy to add to any portfolio, and can offer enhanced yield from stock holdings, in some case, that can be a significant increase.

XLF : 55.33 (+0.02%)
NEM : 106.21 (+1.27%)
MRK : 104.79 (+0.07%)
XOM : 118.36 (+0.18%)
PFE : 25.27 (+0.24%)
WMT : 112.68 (+0.07%)
Dividend Stocks for 2026: Where to Invest as the Market Cools

These three dividend heavyweights offer attractive yields and upside potential heading into what could be an uncertain 2026.

KO : 70.27 (+0.09%)
MRK : 104.79 (+0.07%)
MPLX : 53.76 (+0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 110.86
2nd Resistance Point 107.91
1st Resistance Point 106.31
Last Price 104.79
1st Support Level 101.76
2nd Support Level 98.81
3rd Support Level 97.21

See More

52-Week High 105.84
Last Price 104.79
Fibonacci 61.8% 93.41
Fibonacci 50% 89.57
Fibonacci 38.2% 85.74
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar